Edition:
India

Dynavax Technologies Corp (DVAX.OQ)

DVAX.OQ on NASDAQ Stock Exchange Capital Market

18.75USD
2:29am IST
Change (% chg)

$-0.25 (-1.32%)
Prev Close
$19.00
Open
$18.90
Day's High
$19.45
Day's Low
$18.50
Volume
186,939
Avg. Vol
397,540
52-wk High
$24.45
52-wk Low
$3.75

Chart for

About

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of... (more)

Overall

Beta: 1.45
Market Cap(Mil.): $1,380.17
Shares Outstanding(Mil.): 59.75
Dividend: --
Yield (%): --

Financials

Dynavax's hepatitis B vaccine gets FDA nod on third try, shares up

Dynavax Technologies Corp's hepatitis B vaccine won the U.S. Food and Drug Administration's approval on the third attempt and Chief Executive Eddie Gray told Reuters the company was open to, but not waiting for, a partner to market the drug.

10 Nov 2017

BRIEF-Dynavax says FDA approves Heplisav-B for Hepatitis B prevention in adults

* Dynavax announces FDA approval of Heplisav-B for prevention of Hepatitis B in adults

10 Nov 2017

BRIEF-Dynavax reports Q3 loss per share $0.38

* Q3 earnings per share view $-0.47 -- Thomson Reuters I/B/E/S

03 Nov 2017

BRIEF-Dynavax initiates clinical trial in non-small cell lung cancer with a novel inhaled TLR9 Agonist

* Dynavax initiates clinical trial in non-small cell lung cancer with a novel inhaled TLR9 Agonist in combination with Anti-PD-1 therapy

19 Oct 2017

Immunotherapy developer Dynavax explores options for Hepatitis B drug - sources

Dynavax Technologies Corporation, a biotechnology company focused on drugs that harness the immune system to combat disease, is reviewing strategic options for its hepatitis B vaccine, which could include a potential sale or licensing deal, people familiar with the matter said.

30 Sep 2017

Exclusive: Immunotherapy developer Dynavax explores options for Hepatitis B drug-sources

Dynavax Technologies Corporation, a biotechnology company focused on drugs that harness the immune system to combat disease, is reviewing strategic options for its hepatitis B vaccine, which could include a potential sale or licensing deal, people familiar with the matter said.

30 Sep 2017

BRIEF-Dynavax Technologies says ‍on August 21 court entered an order preliminarily approving a proposed settlement​

* Dynavax Technologies Corp says ‍on August 21 court entered an order preliminarily approving a proposed settlement​

02 Sep 2017

BRIEF-Vectura says global development agreement with Dynavax

* VECTURA'S AKITA SMART NEBULISER TO BE USED BY DYNAVAX TO DELIVER DV281

16 Aug 2017

BRIEF-Dynavax announces exercise in full of over-allotment option

* Dynavax announces exercise in full of over-allotment option and completion of public offering of common stock Source text for Eikon: Further company coverage:

16 Aug 2017

BRIEF-Dynavax announces proposed public offering of common stock

* Dynavax Technologies Corp - ‍intends to offer and sell $125.0 million of shares of its common stock​

09 Aug 2017

Competitors

Earnings vs. Estimates